Research Topics
| Ernest HawkSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Aspirin: anticolorectal adenocarcinoma activity in the adjuvant arena?Ernest Hawk
University of Texas MD Anderson Cancer Center, Division of Cancer Prevention and Population Sciences, Houston, TX 77030 1439, USA
Future Oncol 6:197-200. 2010....
The Translational Research Working Group developmental pathway for lifestyle alterationsErnest T Hawk
National Cancer Institute, Bethesda, Maryland, USA
Clin Cancer Res 14:5707-13. 2008..This article discusses key issues associated with the development of lifestyle alterations in light of the pathway...
Translational Research Working Group developmental pathway for biospecimen-based assessment modalitiesSudhir Srivastava
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
Clin Cancer Res 14:5672-7. 2008..This paper introduces the pathway in the context of prior work and discusses key challenges associated with the biomarker development process in light of the pathway...- The Translational Research Working Group developmental pathways: introduction and overviewErnest T Hawk
Office of Centers, Training, and Resources, National Cancer Institute, Rockville, Maryland, USA
Clin Cancer Res 14:5664-71. 2008..Further development of the pathways is encouraged, as is application of the pathway concept to translational research on other diseases... - What is the future of oncology? National Cancer Institute initiatives to improve research, development, and implementation in cancer prevention and treatmentErnest Hawk
Office of Centers, Training, and Resources, National Cancer Institute OD, Bethesda, MD, USA
Semin Oncol 33:S6-9. 2006.... - Biomarkers, bundled payments, and colorectal cancer careWilliam Ross
Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Genes Cancer 3:16-22. 2012..This promising scenario is still in the future, but progress is being made, and the shape of things to come for cancer care in the age of genomics is becoming clearer... - Chemoprevention--history and general principlesXiangwei Wu
The University of Texas, M D Anderson Cancer Center, Department of Clinical Cancer Prevention, Houston, TX 77030, USA
Best Pract Res Clin Gastroenterol 25:445-59. 2011..In less than four decades, cancer chemoprevention has transformed from a concept to an achievable reality... - GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomesJingyao Dai
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Carcinogenesis 33:1327-31. 2012..Our results suggest that cancer susceptibility loci may also affect the prognosis of CRC patients receiving fluorouracil-based adjuvant chemotherapy... - Celecoxib treatment alters the gene expression profile of normal colonic mucosaOleg K Glebov
Genetics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, Maryland, USA
Cancer Epidemiol Biomarkers Prev 15:1382-91. 2006.... - Cancer prevention and the American Society of Clinical OncologyScott M Lippman
The University of Texas M.D. Anderson Cancer Center, Houston, USA
J Clin Oncol 22:3848-51. 2004 - Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forwardGary J Kelloff
National Cancer Institute, Bethesda, Maryland 20852, USA
Clin Cancer Res 12:3661-97. 2006.... - COX-2 in cancer--a player that's defining the rulesErnest T Hawk
J Natl Cancer Inst 94:545-6. 2002 - Epidemiology and prevention of colorectal cancerErnest T Hawk
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
Surg Clin North Am 82:905-41. 2002..The challenges and rewards of participation in chemoprevention research--both as patients and health care providers-have never been greater... - Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancerVernon E Steele
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892 7322, USA
Mutat Res 523:137-44. 2003..As newer more specific drugs are developed with few adverse effects this important prevention strategy may become a reality... - Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trialsErnest T Hawk
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA
Prog Exp Tumor Res 37:210-42. 2003 - Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancersGary J Kelloff
National Cancer Institute, Division of Cancer Treatment and Diagnosis, Biomedical Imaging Program, Bethesda, Maryland 20892, USA
Cancer Epidemiol Biomarkers Prev 12:593-6. 2003 - Development of COX inhibitors in cancer prevention and therapyAsad Umar
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland 20892-7317, USA
Am J Clin Oncol 26:S48-57. 2003..Discovering how to apply NSAIDs in persons with-or at risk for-cancer, although challenging, has the potential for considerable clinical and public health benefits... - Workshop on imaging science development for cancer prevention and preemptionGary J Kelloff
NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
Cancer Biomark 3:1-33. 2007..Imaging devices, alone or in combination with anticancer drugs, may also provide novel interventions to treat or prevent precancer... - Frontiers in cancer prevention researchAnita L Sabichi
Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
Cancer Res 63:5649-55. 2003 - Do statins prevent cancer?Ernest T Hawk
Office of Centers, Training and Resources at the National Cancer Institute, Bethesda, MD 20892, USA
Nat Clin Pract Oncol 3:478-9. 2006 - Cyclooxygenase inhibition in cancer prevention and treatmentWilliam F Anderson
Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, EPN, Room 2141, 6130 Executive Boulevard, Bethesda, MD 20892-7317, USA
Expert Opin Pharmacother 4:2193-204. 2003..A brief discussion on the pharmacoeconomic considerations of NSAID and COXIB use and safety issues that have recently been the focus of debate, will be presented... - The role of cyclooxygenase inhibitors in cancer preventionWilliam F Anderson
Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Room 2141, 6130 Executive Boulevard, Bethesda, MD 20892-7317, USA
Curr Pharm Des 8:1035-62. 2002..Nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) -1 and -2 are among the most promising classes of agents for targeted molecular prevention...